ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Ultrasound Therapy for Fibromyalgia and Lyme Disease

Curcumin: The All In One Solution, Part 2

What Are the Benefits of Vitamin K2?

Vitamin D deficiency + high fat diet = metabolic syndrome

Why You Should Take Your Apple Cider Vinegar at Night

Use Burdock Oil to Promote Healthy Hair Growth

Meet Your Weight Loss Goals

People with forms of early-onset Parkinson's disease may benefit from boosting niacin in diet, resea...

AMA journal associates iron deficiency with hearing loss

Why the Mediterranean Diet Is so Successful

Print Page
Email Article

A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome – Source: Sleep Medicine, Jan 14, 2011

  [ 19 votes ]   [ Discuss This Article ]
By N Silver, et al. • • January 20, 2011

Background: Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments.

Currently, the most commonly prescribed treatment for RLS is one of the dopamine (DA) agonists. Most of what we understand about efficacy and side effects of the DA agonists are, however, derived from relatively short-term studies.

This is particularly a problem since these medications produce in some patients a significant increase or augmentation of RLS symptoms known to occur during the first 2 years of treatment and perhaps even later in treatment.

The primary aim of this study was to determine the long-term efficacy (10-year) for commonly used RLS medication types: dopaminergic agonists and opioids.

Methods: Records of all RLS patients treated in one tertiary care center with:

Pramipexole [aka Mirapex and other brand names, a “non-ergoline-based” dopamine agonist also used for early Parkinson’s and experimentally for cluster headache, depression, and fibromyalgia],

Pergolide [aka Permax and other brand names, an ergoline-based dopamine agonist also used in some countries to treat Parkinson’s and by veterinarians for some conditions in animals; withdrawn from the US market in 2007]

• Or methadone [aka Symoron and scores of other brand names, a synthetic opioid also used as an anti-addictive for patients on opioids, for pain, and as a cough suppressant]

…. during the years 1997-2007 were reviewed.

The duration and reason for any discontinuation of treatment and medication doses were recorded.

Annual rates for discontinuing treatment persisted for up to 10 years of treatment and were fairly constant after the first year at:

• 9% for pramipexole,

• 8% for pergolide,

• And 0% for methadone.

Similarly, annual augmentation [symptom worsening] rates were fairly constant after the first year and persisted for up to 10 years at:

• 7% for pramipexole,

• 5% for pergolide,

• And 0% for methadone.

The percentage continuing on the treatment medication for over 5 years was 58% for pramipexole and 35% for pergolide.


The DA agonists appear to have a limited period of clinical utility for many patients.

Severe augmentation, while not common in any 1 year, can develop even after years on the medication.

Methadone, in contrast, shows neither augmentation nor major problems with continued efficacy after the first year of treatment.

[Note: Another type of drug – gabapentin, aka Neurontin - may improve RLS symptoms according to a recent 52-week trial, but long term results are not known. Gapapentin is an anticonvulsive GABA analog drug used to treat post-shingles nerve pain and depression.]

Source: Sleep Medicine, Jan 14, 2011. PMID: 21239226, by Silver N, Allen RP, Senerth J, Earley CJ. Johns Hopkins University, Dept. of Psychology and Brain Sciences, 3400 N Charles St., Baltimore, Maryland, USA.

Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

NAD+ Ignite with Niagen

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
A Hard-Working Molecule that May Help Ease Pain & Brighten Mood A Hard-Working Molecule that May Help Ease Pain & Brighten Mood
Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Live Without Anxiety or Stress Live Without Anxiety or Stress

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map